Topics

As Sangamo Touts Data, BioMarin Preps Hemophilia Gene Therapy For FDA

07:49 EDT 8 Jul 2019 | Xconomy

[Updated 7/8/19, 9:22 am. See below.] Gene therapy for hemophilia is as close as it’s ever been to market. And the race to get there got more heated this past weekend at a medical meeting in Australia. At the International Society on Thrombosis and Haemostasis meeting in Melbourne, Sangamo Therapeutics (NASDAQ: SGMO) and partner Pfizer […]

Original Article: As Sangamo Touts Data, BioMarin Preps Hemophilia Gene Therapy For FDA

NEXT ARTICLE

More From BioPortfolio on "As Sangamo Touts Data, BioMarin Preps Hemophilia Gene Therapy For FDA"

Quick Search

Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...